X. Su

发表

Preparation of the Extracellular Domain of GLP-1 Receptor and Its Interaction with GLP-1

Zhengding Su, Hongjian Li, X. Su, 2017 .

An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma

Meizhuo Zhang, G. Zhu, Q. Ji, 2015, Genes, chromosomes & cancer.

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas

Daoqiang Tang, P. Gavine, X. Su, 2014, OncoTargets and therapy.

Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer

Jiaqi Huang, Liyan Jiang, Yihong Yao, 2017, Journal of Cancer.

RET mutation and expression in small cell lung cancer

Shilei Zhang, Yun Sun, X. Su, 2017 .

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2013, Journal of Translational Medicine.

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer

Hongbing Shen, D. Shen, Song Wu, 2016, PLoS genetics.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

R. Herbst, P. Elvin, A. Platt, 2015, BMC Cancer.

Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models

Yun Sun, P. Gavine, X. Su, 2015, Pathology & Oncology Research.

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity

Meizhuo Zhang, P. Gavine, X. Su, 2015, PloS one.

Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.

G. Zhu, Yanying Shen, X. Su, 2013, World journal of gastroenterology.

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis

Meizhuo Zhang, P. Gavine, X. Su, 2015, PloS one.

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

Yingyong Hou, G. Zhu, Shaohua Lu, 2012, Journal of Translational Medicine.

Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models

Weiguo Qing, Fengmin Zhou, W. Su, 2015, Molecular oncology.

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)

D. Shen, B. Han, Haiyi Jiang, 2017, Oncotarget.

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

H. Grabsch, S. Im, C. Womack, 2014, British Journal of Cancer.

The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer.

Lin Xu, Q. Ji, Jia Huang, 2014, Lung cancer.

Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets

Shuqiong Fan, Lili Tang, Jiafu Ji, 2014, Genes, chromosomes & cancer.

Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Edward S. Kim, X. Wang, I. Wistuba, 2013, Clinical Cancer Research.

Oncogenic HER2 fusions in gastric cancer

J. Ji, Lianhai Zhang, G. Zhu, 2015, Journal of Translational Medicine.

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

Wei Zhu, C. Morehouse, Jiaqi Huang, 2013, Cancer genetics.

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

J. Ji, Lianhai Zhang, E. Kilgour, 2013, Clinical Cancer Research.

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

Z. Qian, Y. Sun, C. Liu, 2014, British Journal of Cancer.

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

Roman K. Thomas, Paul D. Smith, E. Kilgour, 2012, Clinical Cancer Research.

Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients

Liying Zhang, Jiayuan Li, Xuehua Zhu, 2016, PloS one.

Abstract 1643: AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer modelsin vitroandin vivo

E. Kilgour, Q. Ji, X. Su, 2011 .

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

Yingyong Hou, G. Zhu, Shaohua Lu, 2012, Journal of Translational Medicine.

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2013, Journal of Translational Medicine.

Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients

Yanying Shen, P. Gavine, X. Su, 2015, PloS one.

Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target

Jing Li, Z. Qian, Q. Ji, 2014, Cancer biology & therapy.